ArticleFrontiers in human neuroscience2025
Domain-specific cognitive screening in acute first-ever stroke: a comparative study of the Oxford Cognitive Screen (OCS) and ACE-III.
Article in Frontiers in human neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond cognition in post-stroke cognitive impairment: neuropsychiatric symptoms and stroke-specific cognitive screening.Cerebral circulation - cognition and behavior · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Post-stroke cognitive impairment (PSCI) is common and often under-recognized, particularly in the acute phase. Most cognitive screening tools provide only a global score, overlooking domain-specific deficits that influence functional recovery. The Addenbrooke's Cognitive Examination-III (ACE-III) is a comprehensive cognitive test whose utility for acute stroke patients remains under-studied. This study evaluated the diagnostic performance of the ACE-III against the stroke-specific Oxford Cognitive Screen (OCS) in detecting PSCI following first-ever stroke in the acute period. Methods: Patients with first-ever stroke and no history of cognitive impairment were prospectively assessed within seven days of onset using both the OCS and ACE-III. PSCI was defined by impairment in one or more cognitive domains on the OCS. The discriminatory capacity of the ACE-III for detecting PSCI was examined, and associations between specific cognitive deficits and functional dependence were analyzed. Results: The OCS detected PSCI in 70% of the 30 patients that were recruited. The ACE-III demonstrated good discriminatory capacity (AUC = 0.897); however, it failed to detect PSCI in five patients identified by the OCS, and misclassified two aphasic but cognitively intact patients as impaired. Two patients classified as impaired on ACE-III were deemed cognitively intact by OCS, underscoring its limitations in stroke populations. Standard and stroke-specific ACE-III cut-offs demonstrated suboptimal accuracy for acute screening. Conclusion: While ACE-III performs well at the group level, it may miss relevant cognitive impairment in the acute stroke setting. Domain-based, stroke-specific tools such as the OCS more reliably detect deficits and may offer greater clinical utility for early cognitive profiling and rehabilitation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.